In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood–brain barrier: toward earlier diagnosis of Alzheimer's disease by molecular imaging
Authors:
- 5 October 2014
- journal article
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 10 (3) , 211-224
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder most often diagnosed 10 years after its onset and development. It is characterized by the accumulation of amyloid‐β peptide (ABP) into amyloid plaques between nerve cells, which produces a massive local neurodegeneration. Molecular magnetic resonance imaging allows diagnosis of AD by showing ABP accumulation in the brain. The ultrasmall particles of iron oxide (USPIO) derivatives proposed in the present work were functionalized with peptides that present an affinity for ABP, independently of its state of aggregation. Their nanomolar Kd* confirms the high affinity of our vectorized contrast agents (VCA) for ABP and therefore their high labeling potential, specificity and sensitivity. Their lack of toxicity has been demonstrated, both by in vitro studies using the MTT method on several cell types, and by in vivo investigations with assessment of renal and hepatic biomarkers and by histopathology evaluation. The results of biodistribution studies corroborated by MRI demonstrate that USPIO‐PHO (USPIO coupled to peptide C‐IPLPFYN‐C) are able to cross the blood–brain barrier without any facilitating strategy, and accumulates in the brain 90 min after its injection in NMRI mice. None of the USPIO derivatives were found in any organs one week after administration. To conclude, USPIO‐PHO seems to have a genuine potential for labeling amyloid plaques in the brain; it has a nanomolar binding affinity, no toxic effects, and its elimination half‐life is about 3 h. Further tests will be made on transgenic mice, aimed at confirming the potential of early AD diagnosis using our VCA. Copyright © 2014 John Wiley & Sons, Ltd.Keywords
Funding Information
- Fonds National de la Recherche Scientifique
- STICHTING VOOR ALZHEIMER ONDERZOEK – FONDATION POUR LA RECHERCHE SUR LA MALADIE D’ALZHEIMER (11023)
- UMons-100 fellowship
This publication has 50 references indexed in Scilit:
- The Role of Tau in Alzheimer's Disease and Related DisordersCNS Neuroscience & Therapeutics, 2011
- The history of the cholinergic hypothesisBehavioural Brain Research, 2011
- Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's diseaseNeurobiology of Aging, 2010
- Controlled in situ preparation of Aβ(1–42) oligomers from the isopeptide “iso-Aβ(1–42)”, physicochemical and biological characterizationPeptides, 2010
- Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate UptakeNeuron, 2009
- Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers DiseaseCurrent Alzheimer Research, 2007
- Fibrillar and Oligomeric β‐Amyloid as Distinct Local Biomarkers for Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 2007
- Aβ Oligomers – a decade of discoveryJournal of Neurochemistry, 2007
- Oxidative Stress, Antioxidants and Neurodegenerative DiseasesCurrent Pharmaceutical Design, 2005
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002